Brief: Prime Medicine Unveils Program For The Treatment Of Alpha-1 Antitrypsin Deficiency (AATD)
18/03/2025 11:05
March 18 (Reuters) - Prime Medicine Inc PRME.O: PRIME MEDICINE UNVEILS PROGRAM FOR THE TREATMENT OF ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) PRIME MEDICINE INC: EXPECTS TO FILE IND AND/OR CTA IN MID-2026 Source text: ID:nGNX9vnd52 Further company coverage: PRME.O ((Reuters.Briefs@thomsonreuters.com))
Recent news on Prime Medicine
See all newsBrief: Prime Medicine Announces U.S. FDA Clearance Of Investigational New Drug Application For Pm647 In Alpha-1 Antitrypsin Deficiency
Prime Medicine, Inc. reports results for the quarter ended June 30 - Earnings Summary
Prime Medicine Q2 net loss narrows on lower expenses
Brief: Prime Medicine, Inc. Q2 EPS USD -0.24
Brief: Prime Medicine Announces U.S. FDA Clearance Of Investigational New Drug Application For Pm577a In H1069q-Mutated Wilson Disease